12 October 2023  
EMA/CHMP/435644/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Praluent 
alirocumab 
On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Praluent. The marketing authorisation holder for this medicinal product is Sanofi Winthrop Industrie. 
The CHMP adopted an extension to the existing indication to include treatment of patients 8 years of age 
and older with heterozygous familial hypercholesterolaemia (HeFH). For information, the full indications 
for Praluent will be as follows:2  
Primary hypercholesterolaemia and mixed dyslipidaemia  
Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and 
non-familial) or mixed dyslipidaemia, and in paediatric patients 8 years of age and older 
with heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet: 
in combination with a statin or statin with other lipid lowering therapies in patients unable to 
reach LDL-C goals with the maximum tolerated dose of a statin or, 
alone or in combination with other lipid-lowering therapies in patients who are statin-
intolerant, or for whom a statin is contraindicated. 
Established atherosclerotic cardiovascular disease  
Praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce 
cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:  
in combination with the maximum tolerated dose of a statin with or without other lipid-
lowering therapies or, 
alone or in combination with other lipid-lowering therapies in patients who are statin-
intolerant, or for whom a statin is contraindicated. 
- 
- 
- 
- 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
For study results with respect to effects on LDL-C, cardiovascular events and populations studied 
see section 5.1. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Praluent  
EMA/CHMP/435644/2023 
Page 2/2 
 
 
 
 
